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Abstract
For patients with end-stage lung diseases, lung transplantation is the only available therapeutic
option. However, the number of suitable donor lungs is insufficient and lung transplants are
complicated by significant graft failure and complications of immunosuppressive regimens. An
alternative to classic organ replacement is desperately needed. Engineering of bioartificial organs
using either natural or synthetic scaffolds is an exciting new potential option for generation of
functional pulmonary tissue for human clinical application. Natural organ scaffolds can be
generated by decellularization of native tissues; these acellular scaffolds retain the native organ
ultrastructure and can be seeded with autologous cells toward the goal of regenerating functional
tissues. Several decellularization strategies have been employed for lung, however, there is no
consensus on the optimal approach. A variety of cell types have been investigated as potential
candidates for effective recellularization of acellular lung scaffolds. Candidate cells that might be
best utilized are those which can be easily and reproducibly isolated, expanded in vitro, seeded
onto decellularized matrices, induced to differentiate into pulmonary lineage cells, and which
survive to functional maturity. Whole lung cell suspensions, endogenous progenitor cells,
embryonic and adult stem cells, and induced pluripotent stem (iPS) cells have been investigated
for their applicability to repopulate acellular lung matrices. Ideally, patient-derived autologous
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cells would be used for lung recellularization as they have the potential to reduce the need for
post-transplant immunosuppression. Several studies have performed transplantation of
rudimentary bioengineered lung scaffolds in animal models with limited, short-term functionality
but much further study is needed.
Keywords
lung; tissue engineering; decellularization; recellularization; stem cells
Introduction
Many devastating lung diseases including chronic obstructive pulmonary diseases (COPD),
idiopathic pulmonary fibrosis (IPF), and cystic fibrosis, among others, have no cure and
cause significant morbidity and mortality. Further, unlike other major diseases, lung
diseases, notably COPD are increasing in prevalence and COPD is predicted to be the third
leading cause of death worldwide by the year 20201,2. Currently, patients with end stage
lung diseases are limited to lung transplantation as their only treatment option.
Unfortunately, there are few available lungs for transplant, 5 year survival after lung
transplantation is only approximately 50%, and transplantation recipients require lifelong
immunosuppression1,2. New options are desperately needed.
A promising and rapidly growing area of investigation is that of ex vivo bioengineering of
functional lung tissue that could then be implanted into patients with diseases such as COPD
or IPF. This could be accomplished by utilizing either biologically-derived or fabricated 3
dimensional (3D) matrices or other artificial scaffolding seeded with autologous stem,
progenitor, or other cells obtained from the eventual transplant recipient. The use of
autologous cells would eradicate the need for lifelong immunosuppressive drugs. These
approaches have been successfully utilized in regeneration of other tissues including skin,
vasculature, cartilage, bone, and trachea and more recently more complex organs including
heart and liver3–15. Synthetic constructs offer one option and a number of different synthetic
scaffold materials and manufacturing technologies have been evaluated for use to produce
matrices for ex vivo lung parenchymal development and for the study of growth factors and
mechanical forces on lung remodeling16–21. These studies have included implantation of
various scaffolds impregnated with stem or other cells in order to produce functioning lung
tissue22–25. Comparable approaches have been utilized to study creation of pulmonary
vascular networks from synthetic scaffolds and to investigate effects of vascular endothelial
cells on development of airway and alveolar epithelial tissues26,27. However, current state-
of-the-art manufacturing technologies are unable to recapitulate the complex 3- dimensional
architecture of the lung and, further, robust schemes for successful implantation and clinical
use of synthetic lung scaffolds remain unknown.
An alternative approach is to utilize whole lungs in which all cells and cellular materials are
removed leaving an intact 3-dimensional scaffold comprised of innate extracellular matrix
(ECM) proteins in a bio-mimetically similar 3-dimensional architecture. This approach,
termed decellularization, preserves native airway and vascular structure and provides an
acellular matrix for cell seeding and functional recellularization3,28–30. This approach also
provides a novel culture system to study cell-matrix interactions and environmental factors
such as mechanical stretch on lung cell growth and development. This technique was
originally described many years ago, one classic example is by Lwebuga- Mukasa and
colleagues in 1986 in which a decellularized rat lung was utilized to study the effect of the
basement membrane on growth of type II alveolar epithelial (AEII) cells30. The technique
Wagner et al. Page 2
Respirology. Author manuscript; available in PMC 2013 August 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
was re-invigorated in 2010 and a number of laboratories are currently exploring this
approach (Table 1) 31–44.
In this review, we will address some of the critical factors involved in the theoretical and
practical considerations for use of decellularized whole lungs (alternatively referred to as
acellular) for ex vivo lung regeneration. These include decellularization and recellularization
procedures as well as consideration of the potential immunogenicity of the scaffolds
(schematic in Figure 1). We will also speculate as to the logistics involved in
implementation of this approach for lung diseases. Finally, we discuss the feasibility of
employing acellular scaffolds for ‘repopulation assays’ of stem-progenitor cells.
Review
Decellularization
Methods of Decellularization—Creation of organ scaffolds requires removal of the
native cell population while minimizing alterations to the dimensions and mechanical
characteristics of the organ, the structural support for the airway, vascular and lymphatic
networks, and to the composition of the native matrix including important cell binding
ligands3. Common methods for decellularization of lung tissue pieces include sonication,
sieving, and extraction of thin pieces of lung tissue and digestion with acetic acid followed
by sonication. While useful techniques for developing in vitro systems to study lung
biology, these methods did not preserve the 3 dimensional architecture of the lung. Recently,
several techniques have emerged for decellularizing whole lungs which retain the 3
dimensional architecture as well as key extracellular matrix proteins (Table 2, Figure 2).
These techniques vary significantly with use of different combinations of physical, ionic,
chemical and enzymatic methods and procedure times that vary between 2 hours to 7 weeks.
Detergent-based decellularization is a frequently utilized approach and commonly used
detergents include Triton X100, sodium deoxycholate (SDC), sodium dodecyl sulfate (SDS),
and CHAPS in addition to hypertonic lysis of cells with NaCl as well as a DNAase and/or
RNAase. Furthermore, some investigators employed both vascular and airway perfusion
with these agents while others have only perfused through the vasculature. As such,
significant differences in histologic appearance of the decellularized lungs and in content of
both ECM and other retained proteins occur in the various published works evaluating the
quality of decellularized lungs. How these differences might affect recellularization or
potential immunogenicity of the implanted scaffold are still poorly understood. Some
proposed criteria for optimal decellularization include complete absence of visible cellular
or nuclear material on histological examination, less than 50ng of dsDNA per 1 mg of dry
weight of the extracellular matrix scaffold and remnant DNA molecules shorter than 200
bp3,40. However, further study is needed to understand and define optimal endpoints for
decellularization. Other criteria such as retention of specific ECM components and
maintenance of macro and micro-mechanical properties are likely critical parameters in
defining optimal decellularized scaffolds.
Residual Extracellular Matrix and Other Proteins—The lung is composed of a
variety of cells and associated extracellular matrix (ECM). The ECM has an essential role in
prenatal development, postnatal maintenance of normal function, and is known to be an
inductive scaffold in directing the remodeling response after injury45–49. The ability of cells
to receive organotypic signals from native ECM makes decellularized scaffolds a seemingly
better choice than synthetic constructs for tissue engineering. Therefore, retention of key
ECM components is essential in the decellularization process. Which combination of ECM
proteins must be retained to maintain critical cues for cell functions remains unknown.
Further, the detergents utilized during the decellularization process can activate matrix
metalloproteinases and thus potentially exacerbate degradation of critical binding epitopes
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on the remaining ECM proteins41. The major structural and functional molecules in the
ECM include glycosaminoglycans (GAGS) and the collagens, elastin, fibronectin, laminin,
and vitronectin. Collagens are important structural components of the lung and are
responsible for overall mechanical strength. Elastin is an important ECM protein for
providing the reversible distension and intrinsic recoil properties of lung tissue. GAGs help
control macromolecular and cellular movement across the basal lamina and may play a role
in the mechanical integrity of the lung. These matrix molecules are generally highly
conserved proteins in eukaryotic organisms and theoretically may explain the absence of an
adverse immune response after xenotransplantation as seen with some other decellularized
organ transplants such as the tracheal patch14,15. However, some ECM proteins, for example
collagen V, are postulated to play significant immunogenic roles in rejection of lung
transplantation50. Laminin, fibronectin, elastin, and collagens I and IV have also been found
to play a role in trans-membrane cell signaling, cellular differentiation, respiratory
mechanics and other pulmonary-specific functions46–49.
The ECM components remaining in decellularized lung scaffolds can be evaluated using a
combination of histologic, immunohistochemical, and Western blotting techniques (Table
1). In most instances, the decellularization process largely preserves collagen but results in a
moderate loss of elastin31–33,38–43. In one study, comparison of different detergents in the
decellularization process revealed that SDS was associated with a greater loss of type 1
collagen and elastin when compared with CHAPS44. Another study demonstrated that
different detergent based de-cellularization protocols result in significant differences in
histologic appearance, gelatinase activation, distribution of ECM components, and lung
mechanics41. However, despite these differences in composition of the lungs, inoculated
cells appeared to attach and recellularize the lung regardless of the decellularization protocol
utilized41. Furthermore, recent investigations of relevant clinical parameters including effect
of donor age, time to necropsy, prior lung injury, length of scaffold storage, and sterilization
method demonstrate that each of these parameters can affect the outcome and histology of
the decellularized scaffold42–43. Therefore, the choice of the lung utilized, method of
decellularization, and clinical storage conditions must, at a minimum, preserve appropriate
ligands to allow adherence, spreading, polarization (if appropriate), and in some cases,
proliferation of cells.
Mass spectrometry is increasingly utilized to identify a broader range of residual ECM
proteins, including isoforms not readily distinguished by the other analytical
techniques38,39,41–43. This approach also demonstrates that a wide range of other non-ECM
proteins are retained in decellularized scaffolds with the current techniques including
intracellular, cytoskeletal, and cell membrane-associated proteins. This suggests that cellular
proteins are not all removed by decellularization protocols, presumably due to tight
anchoring of transmembrane proteins to ECM ligands. Importantly, the spectrum of retained
cellular (non-ECM) proteins differs depending on the decellularization protocol utilized41.
The effects of these cellular proteins on recellularization and potential immunogenicity of
the scaffold is unknown at present but several retained proteins (e.g. histones) are known to
be immunogenic51. Moreover, the range of different GAGs that are retained which may be
important for recellularization and contribute to potential immunogenicity has not been well
explored52. These are important areas for future study.
Species differences in decellularized lungs—Published data to date includes
decellularization of mouse, rat, sheep, macaque, and human lungs. Our collaborative group
has also accumulated extensive data on decellularization of pig and cadaveric human lungs
(manuscripts in preparation). While there are no obvious substantive differences in the final
decellularized lungs from each species, differences in lung and pleural anatomy may
significantly affect the decellularization process. Further, decellularizing larger lungs
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requires practical modifications of detergent-based techniques including close attention to
rate and volume of solutions used to perfuse and wash the more cumbersome larger lungs.
Special consideration needs to be taken for decellularizing human lungs under appropriate
containment conditions including use of appropriate antimicrobial agents and an appropriate
post-decellularization sterilization protocol.
Functionality of the Decellularized Scaffold—In vitro evaluation of the “function” of
the decellularized scaffolds can be challenging. It is not clear what type of functional
assessments best reflect the ability of decellularized lung scaffolds to support
recellularization and ultimately development of functional lung tissue. Investigators have
explored mechanical function including assessment of lung mechanics39–41 as well as force
tension relationships in linear strips of decellularized lungs44. These methods give an
indication of the elastance, compliance, resistance, and diffusion properties of the scaffolds.
However, in the absence of cells and surfactants, the decellularized lungs are stiff, a factor
that must be taken into account for recellularization schemes using bioreactor technology.
One potential bioassay to follow over time as the lungs are recellularized is the decrease in
elastance (increase in compliance) due to growth and maintenance of a functional population
of surfactant-producing cells39. Total lung water, normally controlled by endothelial,
lymphatic, and type I alveolar epithelial cells might also be important to monitor but no
guidelines have been established for these endpoints.
Recellularization of acellular scaffolds for bioengineering and assays of organotypic
repopulation
The lung is comprised of many (>40) cell types that are replenished by resident stem or
progenitor cells following injury. However, there is much debate concerning the
identification and nature of different types of endogenous lung stem/progenitor cells that can
function in repair53–55. Notably, this area of research has been hampered by the lack of
robust assays of endogenous stem/progenitor cell function including an accurate
repopulation assay. Repopulation assays are critical for verifying the capacity for
multipotency, self-renewal (i.e. stemness), and for establishing the heterogeneity of stem,
progenitor, and progeny cells, and characterization of cell niches, as evidenced by their
long-standing application to studies of hematopoiesis. Repopulation studies using single
cells, clonally-derived populations, or mixed cell populations further provide an
understanding of their spatial (i.e., homing, niche), functional (secretory, paracrine, matrix
synthesis, self-renewal, differentiation), and population (kinetics, heterogeneity)
characteristics. As such, one potential novel and important use of decellularized lung
scaffolds is as a matrix for repopulation assessments. This further allows unique
opportunities to study abnormal matrices obtained from diseased lungs43,56.
Seeding decellularized lung scaffolds with whole lung fetal or post-natal cell suspensions
has the potential advantage of providing a model of spontaneous self-assembly and
facilitating natural cell-cell interactions that could potentially improve organotypic growth.
When fetal rat (E17) whole lung suspensions were delivered intratracheally to decellularized
rat lungs and cultured in a bioreactor, cells adherent in the alveolar compartment expressed
markers of ATII (CK18 and pro-surfactant C (proSPC)); markers of type I alveolar epithelial
(ATI), endothelial, mesenchymal, or club cells (formerly known as Clara cells) were
absent31. E17 lung cells are enriched for ATII cells so it is possible that this observation
relates to the difficulty to induce ATII cells to convert to ATI cells under these conditions.
In contrast, seeding with rat fetal lung cells (E17–20) resulted in multilineage engraftment
again, mainly in the alveolar compartment, with expression of markers of ATII cells such as
pro-surfactant A (proSPA), proSPC, thyroid transcription factor (TTF-1/Nkx2.1), ATI
(T1α), and fibroblasts (vimentin); concurrent inoculation with human umbilical vein
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endothelial cells (HUVEC) by way of the pulmonary artery showed retention along the
entire vasculature and close apposition of endothelial and alveolar epithelial cells suggestive
of perfusion of distal lung33. Larger airways were only sparsely engrafted in this model.
Neonatal (P7) whole lung cell suspensions exhibited similar multilineage engraftment
including evidence of distal airway repopulation with club cells (club cell secretory protein
(CCSP+,CC10)) and basal cells (CK14+), as well as alveolar engraftment of ATII cells
(proSPC+) and ATI cells (Aqp5+); endothelium engrafted the pulmonary vasculature and
formed tight junctions32. While it is difficult to ascertain the precise geospatial distribution
of cells, it is clear that fetal or post-natal lung homogenates can repopulate scaffolds with
cells exhibiting a wide range of phenotypes with preferential distribution to the alveoli and
distal airways.
However, fetal lung cells and transformed cell lines are not practical for clinical use in
recellularizing lung scaffolds; therefore, the question arises as to which cells are appropriate
for lung bioengineering applications. While there is still only limited experience, the ability
of other cell types to home or engraft in specific regions of the lung is emerging (Table 3).
Cell types that might be best utilized are those which can be easily and reproducibly
isolated, expanded in vitro, seeded to decellularized matrices, induced to differentiate into
pulmonary lineage cells, and survive to functional maturity. Each of these criteria requires
careful optimization in order to recapitulate the natural tissue environment. In particular, the
human lung is comprised of a complex mix of airway and glandular epithelial cells, mucoid
cells, neuroendocrine cells, and endogenous progenitor cells; all of which exist in a specific
gradient of niches polarized from the proximal to distal airway53. As such, it is logical that
recellularization of decellularized lung scaffolds will require multiple cell types to be seeded
at various stages of differentiation and at specific locations throughout the airway scaffold
for successful tissue regeneration.
Ideally, patient-derived autologous cells would be used for lung recellularization as they
have the potential to reduce the need for post-transplant immunosuppression. Terminally
differentiated cells derived from adult lungs are highly specialized and lose their
proliferative ability by the time they reach this state; therefore, primary airway or vascular
cells, while offering the most functionally diverse options for lung tissue engineering, may
not be capable of long-term success without a source of progenitor cells for maintenance and
repair. A more desirable strategy is one in which stem or progenitor cells are differentiated
along pulmonary lineages following programs that mimic fetal lung development. The ideal
candidate cells must be easily isolated, expanded in culture, and sustained stably while
undergoing tissue-specific differentiation.
Embryonic stem cells (ESCs) derived from the inner mass of in vitro-fertilized embryonic
blastocysts have the potential to differentiate into mature cells of all three germ layers.
Directed differentiation of ESCs results in the production of lineage-specific progenitor cells
that may potentially be used in therapeutic or regenerative applications57. In the laboratory,
lineage specification of ESC has been accomplished by recapitulating the developmental
environment in vitro. Murine ESCs have been induced to express markers of lung epithelial
phenotype including alveolar (TTF-1, SPA and SPC) and airway (CCSP) airway epithelium
after specification of definitive endoderm using Activin A to mimic the Nodal signaling
pathway followed by adherent cell culture in small airways growth medium or use of more
selective differentiation reagants45,58–61. Similar findings using human ESCs have also been
reported62,63. Induced pluripotent stem (iPS) cells, an alternative cell type similar to ESCs
with less ethical controversy, are derived by re-programming somatic cells to a stem-like
state by inducing simultaneous expression of combinations of the transcription factors Oct4,
Klf4, Sox2, and cMyc64,65. iPS cells re-establish pluripotency and, like ESCs, with
appropriate stimulation, can differentiate into lineages of all three germ layers including
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those from which the host cell was not derived. A limitation of iPS cells is that they are not
free from age-, environment-, and tissue-associated epigenetic modifications; therefore,
there is some question as to whether iPS cells will respond developmentally and functionally
as do ESCs. Further, iPS cells, like ESCs carry risk of teratoma formation. Nonetheless, iPS
cells have been shown to be responsive to developmental stimuli for the specification of
anterior foregut endoderm and further differentiation into early lung progenitor
populations60,66. An attractive feature of iPS cell generation is that they may be derived
autologously from a patient, thereby eliminating the need for allogeneic cells and avoiding
much of the controversy associated with ESCs. However, it is unknown as to whether the
genetic manipulation required for creating iPS cells or the epigenetic modifications inherent
in the initial host cells will have any bearing on the ability of iPS cells to create fully
functional tissues that can be used as transplantable substitutes for diseased tissues67.
ESCs or iPS cells or their endoderm derivatives might be expected to reconstitute acellular
lung scaffolds efficiently with progeny upon exposure to instructive cues embedded in the
matrix. Seeding acellular rat scaffolds with mouse ESCs resulted in both greater survival
compared to cells seeded onto non-lung matrices (Matrigel, gelfoam, or collagen) and also
apparent differentiation toward multiple lineages that exhibited region-specific distribution,
including club cells (CC10+), ATII cells (CK18+, proSPC+), endothelial cells (CD31+), and
mesenchymal cells (PDGFRα+)34. Thus it is theoretically possible to observe differentiation
of the most primitive of stem cells along the lines of development simply by seeding them
on acellular scaffolds. However, the efficiency of this system was not explicitly evaluated.
Seeding of decellularized mouse lungs with definitive endoderm derived from ESCs and
subsequent culture of lung slices resulted in spontaneous differentiation to elongated type I
alveolar epithelium expressing T1α (podoplanin) that distributed along the alveolar septae;
in contrast, inoculation with parent ESCs produced hypercellular sheets of disorganized cells
lining both the alveoli and some ciliated cells along airways61. Similarly, mouse ESCs
differentiated to Nkx2.1+, proSPC+ ATII-like cells directly seeded onto mouse acellular
scaffolds that were implanted subcutaneously distributed to airways (FoxJ1pos) and alveolar
regions (proSPC+ or PDGFRα+ cells) and maintained phenotype expression for 14 days40.
In parallel, host-derived endothelial cells infiltrated the scaffolds suggesting that functional
vascularization might occur. These studies also demonstrated that Matrigel as a vehicle for
seeding increased the frequency of proSPC, TTF-1, PDGFRα, and FoxJ1 positive cells after
14 days, implying that biomimetic basement membranes may preserve heterogeneity in
populations of lung endoderm derived from ESC or iPS cells, particularly in the airway
epithelial fractions. However, no data is as yet available examining the behavior of iPS cells
at any stage of differentiation in decellularized lung scaffolds.
The use of more committed cells should better define the fidelity of repopulation including
region-specific distribution. To date, only a limited number of cell types have been
employed, and almost all of these cell types normally inhabit the alveolar compartment. In
one study, ATII cells converted to ATI-like cells (flattening, loss of lamellar bodies,
formation of tight junctions, and synthesis of pinocytotic vesicles) when cultured on
acellular lung but not amniotic matrices, again supporting the specific role of lung matrices
to instruct differentiation of progenitor cells30. In a more recent study, primary or passaged
ATII cells seeded directly onto acellular lung for 22 days maintained proSP-C and mature
SP-C expression with some cells developing expression of Aqp5 and T1α36. Moreover,
fresh ATII cells seeded on lung scaffolds showed CC10 expression although the specific
distribution of these cells was not defined. In other studies, seeding decellularized mouse
lungs with immortalized non-neoplastic mouse ATII cells (C10 cells) resulted in widespread
distribution including predominantly small but also large airways as well as alveolar
regions41–43. This suggests that transformed, and likely also neoplastic, cell lines will not
home specifically to the region inhabited by their cell of origin (i.e. ATII cells) and may
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exhibit atypical morphologies. While these data do not completely resolve the specificity of
homing and engraftment of ATII cells, they suggest that these events are promoted by the
acellular scaffolds acknowledging that the composition and quality of the scaffold is a
critical factors in retention, survival, phenotype, and function during recellularization. Data
concerning regio-specific repopulation of acellular lung scaffolds with specific populations
of basal cells, club cells, neuroendocrine cells, submucosal glandular cells, bronchioalveolar
stem cells (BASC), ciliated or non-ciliated airway epithelial cells, lung fibroblasts, and
microvascular endothelium are lacking.
While the existence of adult endogenous lung epithelial progenitor cells is a topic of great
interest to pulmonary biology, it is unclear how acellular scaffolds will influence the
phenotype and function of these cells. Importantly, our understanding of the specific
features of cellular niches in the lung is limited, and therefore it is unknown how acellular
scaffolds succeed or fail to recapitulate those microenvironemnts. In some areas of lung (e.g.
basal cell layer) the features of a niche are better understood than in others (e.g. alveolus).
Until the features of a niche are known, it may be impossible to distinguish or direct homing
after recellularization to a specific niche (i.e., true ‘repopulation’) from stochastic events.
Exploiting endogenous stem-progenitor cell populations for bioengineering purposes will be
further constrained due to the relatively small number of stem-progenitor cells that inhabit
the lung, and the challenges of isolation, culture, and expansion of those cells while
preserving their native characteristics. Furthermore it remains unknown as to whether
endogenous epithelial progenitor cells obtained from diseased lungs, when placed into an
epigenetically new environment (i.e. acellular scaffold) will adapt to these changes by
restoring function. Thus while many opportunities exist to study fundamental mechanisms
of stem-progenitor cell-scaffold interactions in decellularization-recellularization models, it
will be critical to develop acellular scaffolds and culture conditions that replicate normal
‘homeostatic’ conditions before they are used for bona fide ‘repopulation’ assays akin to
those assays employed for study of hematopoiesis.
The lung also harbors non-endodermal (mesenchymal) sources of progenitor cells. Tissue
stroma in particular appears to be robust sources of mesenchymal stem-like cells that may
participate in tissue maintenance, repair, and immune regulation68. Lung-resident
mesenchymal stem/stromal cells (L-MSCs) have been identified in mice and humans by
fluorescence-activated cells sorting (FACS) for vital dye efflux as well as by adherent cell
culture from bronchioalveolar lavage and lung tissue explants69–71. Recent reports
demonstrate that L-MSCs contributed to lung repair after bleomycin-induced lung injury and
in elastase-mediated injury in murine and ovine models of experimental emphysema70–72.
Co-culture of L-MSCs with ATII cells induced the expression of CK18, CK19, occludin,
and SPC in L-MSCs suggesting that these lung-resident stromal cells have the ability to
differentiate into alveolar-like cells in vitro; however, little is known about whether they
accomplish this in vivo73. Like bone marrow-derived MSC, L-MSCs also exhibit the ability
to differentiate into endothelial-like cells that take up acetylated-LDL when cultured in
endothelial growth medium on appropriate substrates70. L-MSCs may thus be useful in lung
bioengineering strategies as they exhibit several desirable characteristics including tissue
support, regulation, repair, and potentially regeneration70,71,74,75. For example, ovine L-
MSCs were shown to promote epithelial growth in co-culture, engrafted and synthesized
provisional matrices (laminin, fibronectin, collagen IV) on acellular sheep lung scaffolds,
and promoted tissue healing in a sheep model of emphysema74,75 and murine L-MSCs
reversed elastase-induced injury70.
Just as resident mesenchymal stem/stromal cells from the lung may be exploited for
bioengineering, more accessible MSCs isolated from bone marrow (BM-MSCs) and other
sources including adipose and placental tissues may also be potentially utilized in used in
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this context. While it has been demonstrated that BM-MSCs and cord blood-derived MSCs
can differentiate into pulmonary-like cells in vitro when cultured in specialized media or co-
cultured with airway epithelial cells76,77, in vivo engraftment is currently felt to be a rare
phenomenon of no likely physiologic or therapeutic significance54,77–79. However, MSCs
may hold more potential for recellularizing organ scaffolds and have been utilized in
bioengineering schemes utilizing both synthetic and decellularized tracheas14,15. Our
collaborative group has investigated the initial interactions of BM-MSCs with decellularized
lung parenchyma in both murine and non-human primate models to test their applicability
toward regeneration of functional pulmonary tissue38,39,41–43. As with L-MSCs, MSCs from
other sources will most likely have a role to provide a stroma and participate in formation of
niches for epithelial and endothelial cells 80,81.
To best develop repopulation assays using recellularization of acellular scaffolds, it will be
crucial to characterize stem-progenitor cell ‘niches’ in the lung, including the role for
supportive stromal cells and the identity of extracellular matrix ligands that presumably
control the fate and function of cells within and upon release from the niche. In some areas
of lung (e.g. basal cell layer) the features of a niche are better understood than in others (e.g.
alveolus). Until the features of a niche are known, it may be impossible to distinguish or
direct homing to a niche (‘repopulation’) from stochastic phenomena.
Implantation of Recellularized Scaffolds
Several investigators have performed xenotransplantation of decellularized scaffolds into
rodents as well as larger animals. Using decellularized rat lung scaffolds re-epithelialized
with a mixture of rat fetal lung homogenate and A549 lung carcinoma cells, and re-
endothelialized with human umbilical vein endothelial cells, two groups were able to
transplant the repopulated scaffold into rats that had undergone previous
pneumonectomy32,33. Prior to implantation, the repopulated scaffolds were able to maintain
adequate oxygenation, carbon dioxide exchange, and appropriate pressure/volume
relationships. However, once implanted, the grafts developed significant pulmonary edema
and/or hemorrhage resulting in respiratory failure after several hours. In a follow-up study,
survival for fourteen days was achieved after implantation but graft function progressively
declined and the histologic appearance of the graft at necropsy demonstrated significant
fibrosis37. Though these studies are technically innovative and provide proof of concept that
acellular matrices can be repopulated, transplanted, and maintain a degree of function, they
are not yet clinically translatable. In order to have a clinically translatable model, adequate
gas exchange, re-creation of intact alveolar and vascular compartments, unidirectional
mucociliary clearance, immune surveillance, clearance of infection, and maintenance of
physiologic airway pressures and volumes. Thus far, there has been a compartmentalized
approach to the respiratory system, separating the vasculature, proximal airways, and distal
lung. A successful translatable implantation animal model has not yet been created, but will
need to balance all of these requirements. It will likely be a number of years before this is
achieved.
Immunogenicity of Implanted Scaffolds
A critical assumption for clinical use of decellularized lung scaffolds is that they will be
relatively non-immunogenic and minimize any detrimental host response following
implantation. However, ECM and other proteins remaining in decellularized scaffolds can
provoke immune responses82–85. Interestingly, some of these may be beneficial as growing
literature suggests that decellularized scaffolds can polarize macrophages to anti-
inflammatory M2 phenotype with subsequent permissive effects on implanted
scaffolds86–88. With respect to lung, proteomic assessments utilizing mass spectrometry and/
or western blotting demonstrate that a wide range of residual proteins, including
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intracellular, nuclear, cytoskeletal, and others can remain in the lungs, despite apparent
effective de-cellularization38,39,41–43. Whether these residual proteins provoke immune
responses is currently the focus of intense inquiry. Theoretically, despite conservation of
ECM proteins, any denuded basement membrane may provoke an immune response, in part
to mobilize the necessary cells to cover the “damaged” membrane50. Whether cells
inoculated into decellularized scaffolds will secrete ECM and other proteins and remodel the
scaffold accordingly is also the subject of intense current investigation39.
Mechanical Factors in Ex Vivo Lung Regeneration
In addition to utilizing the proper cell type(s) to inoculate into the scaffolds and using
appropriate growth factors, environmental cues such as mechanical stimuli may also play a
critical role. There is a large and growing body of literature that delineates the importance of
various mechanical stimuli on regulating development as well as normal and diseased tissue
homeostasis in vivo. For example, mechanical stretch is known to induce overexpression of
SPC mRNA and protein expression in ATII cells, while shear stress on endothelial cells is
critical for VEGF expression. Several studies have examined the biological consequences of
mechanotransduction on fetal or adult lung cells in vitro85–88 but there is no available
information on effects of stretch on development of lung epithelial tissue from embryonic or
adult stem cells or from endogenous lung progenitor cells. It is likely that in addition to
derivation of an optimal decellularized scaffold, precise control of the mechanical
environment with bioreactor technologies (ie. stimuli mimicking stretch from breathing and
shear stress induced by blood flow) will be necessary for a successful regeneration scheme.
Other environmental factors such as oxygen tension will likely also play critical roles in
recellularization schemes.
Summary
The challenges in developing complex 3-dimensional functional lung tissues ex vivo will be
in recapitulating the normal dynamic integrated network of component cells, orientation and
function of the fiber network, perfusion ventilation relationships, and immune surveillance,
all of which are vital for proper function (92). Whether decellularized lung constructs or
synthetic 3-dimensional lung scaffolds achieve these goals is an area of intense excitement
and study.
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Figure 1. Schematic for optimal decellularization, recellularization, and implantation
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Figure 2. Representative images depicting decellularization, recellularization, and implantation
of decellularized lung scaffolds
A) Whole de-cellularized mouse heart-lung bloc. The trachea is cannulated with a 18 gauge
blunted needle. Reprinted with permission from Daly et al., Initial Binding and Re-
Cellularization of De-Cellularized Mouse Lung Scaffolds with Bone Marrow-Derived
Mesenchymal Stromal Cells Tissue Engineering Part A, Vol. 18, No. 1–2: 1–16, 2012 (39).
B) H and E, Masson’s Trichrome collagen, and Verhoeff’s Van Gieson staining of native
mouse lungs, de-cellularized whole mouse lungs, and approximately 1 mm thick slices of
mouse de-cellularized lungs. Original magnifications: 100 X. a = airway, bv = blood vessel.
Reprinted with permission from Daly et al., Initial Binding and Re-Cellularization of De-
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Cellularized Mouse Lung Scaffolds with Bone Marrow-Derived Mesenchymal Stromal
Cells Tissue Engineering Part A, Vol. 18, No. 1–2: 1–16, 2012 (39).
C) Transmission electron micrograph images of different regions of a representative de-
cellularized whole mouse lung are shown. Original magnifications A) 600X, B) 1,000X, C)
1,000 X, D) 3,000X. Reprinted with permission from Daly et al., Initial Binding and Re-
Cellularization of De-Cellularized Mouse Lung Scaffolds with Bone Marrow-Derived
Mesenchymal Stromal Cells Tissue Engineering Part A, Vol. 18, No. 1–2: 1–16, 2012 (39).
D) Histologic assessment of H and E stained whole mouse lungs de-cellularized using
different detergent-based protocols demonstrates significant differences in resulting
histologic architecture notably loss loss of detail and parenchymal structure when using
CHAPS. a = airway, bv = blood vessel, Original magnifications 100X. Reprinted with
permission from Wallis et al., Comparative assessment of detergent-based protocols for
mouse lung de-cellularization and re-cellularization. Tissue Eng Part C Methods 2012; 18:
420–432 (41).
E) Representative gross and histologic images of native and decellularized macaque lungs.
Reprinted with permission from Bonvillain et al., A nonhuman primate model of lung
regeneration: detergent-mediated decellularization and initial in vitro recellularization with
mesenchymal stem cells. Tissue Eng Part A 2012; 18: 2437–52 (38)→.
F) Intratracheally inoculated MSCs cultured up to one month in both basal MSC media and
in SAGM grow in parenchymal and airway regions of de-cellularized whole mouse lungs.
Representative photomicrographs depict MSCs in large airways (upper row) and in
parenchymal lung regions (lower row). Green arrows highlight cells growing in large
airways, and the asterisk in the upper left-hand image show the region magnified in the
upper right-hand image. Original mags are 100X, 400X, 400X and 200X. Reprinted with
permission from Daly et al., Initial Binding and Re-Cellularization of De-Cellularized
Mouse Lung Scaffolds with Bone Marrow-Derived Mesenchymal Stromal Cells Tissue
Engineering Part A, Vol. 18, No. 1–2: 1–16, 2012 (39).
G) Lung-derived MSCs (L-MSCs) inoculated into decellularized sheep lung scaffolds
express and grown for 2 weeks express a variety of ECM proteins (fibronectin is depicted)
that may help to remodel the scaffold. Reprinted with permission from Ingenito et al,.
Autologous lung-derived mesenchymal stem cell transplantation in experimental
emphysema. Cell Trans 2012; 21: 175–189 (75).
H) Mouse embryonic stem cells (ESCs) pre-differentiated in routine tissue culture to express
pro-surfactant protein C (pro-SPC, red stain) maintain pro-SPC expression after culture in
decellularized mouse lung scaffolds. Depcited are images of native mouse lung and
decllularized mouse lung 1 week after inoculation with SPC-expressing murine ESCs.
Original magnification 200X. Reprinted with permission from Jensen et al., A rapid lung de-
cellularization protocol supports embryonic stem cell differentiation in vitro and following
implantation. Tissue Eng Part C Methods 2012; 18: 632–46 (40).
I) Tissue-engineered left lung was implanted into adult Fischer 344 rat recipient and
photographed ∼30 minutes later. (B). X-ray image of rat showing the implanted engineered
left lung (white arrow) and the right native lung. (C) H and E stain of explanted lung. Red
blood cells perfusing septa are evident, and some red blood cells are present in airspaces.
Scale bar 50 µm. Reprinted with permission from Petersen et al., Tissue-Engineered Lungs
for in Vivo Implantation. Science, 2010 329:538–541 (32).
J) Decellularized sheep lung lobe (white arrow) implanted into an adult sheep establishing
both airway and vascular anastomoses with appropriate inflation and vascular perfusion.
Hoffman, Finck, Weiss unpublished data.
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Table 2
Agents Commonly Used During De-Cellularization
Agent Properties
Triton X-100 Nonionic detergent used to solubilize proteins;
mild non-denaturing detergent
Sodium Deoxycholate (SDC) Water soluble ionic detergent used for disrupting
and dissociated protein interaction
Sodium Dodecyl Sulfate (SDS) Anionic surfactant used for lysing cells and
unraveling proteins
3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate (CHAPS)
Non-denaturing zwitterionic detergent used to
solubilize proteins
Ethylenediaminetetracetic acid (EDTA) Chelating agent that binds to calcium and
prevents joining of cadherins between cells,
preventing clumping of cells grown in liquid
suspension, and detaching adherent cells. Can
also be used to inhibit metalloproteinases.
Antibiotics Typically Penicillin, Streptomycin, and an anti
mycotic Amphotericin
Other DNAase, RNAase, and heparin
Respirology. Author manuscript; available in PMC 2013 August 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Wagner et al. Page 27
Ta
bl
e 
3
D
ist
rib
ut
io
n 
an
d 
ph
en
ot
yp
e 
of
 c
el
ls 
se
ed
ed
 o
nt
o 
ac
el
lu
la
r s
ca
ffo
ld
s.
R
ef
er
en
ce
C
el
ls 
us
ed
fo
r 
se
ed
in
g
Sc
af
fo
ld
R
ou
te
D
ur
at
i
o
n
D
ist
ri
bu
tio
n
Fi
na
l p
he
no
ty
pe
Lw
eg
a-
M
uk
as
a 
et
a
l. 
Ex
p 
Lu
ng
R
es
 1
98
6
(30
)
A
EC
II
A
ce
llu
la
r
al
ve
ol
ar
 v
s.
am
n
io
tic
ba
se
m
en
t
m
em
br
an
es
D
ire
ct
se
ed
in
g
8 
da
ys
N
/A
A
lv
eo
la
r m
at
ric
es
:
A
EC
I; 
am
ni
on
ic
m
em
br
an
es
 A
EC
II
C
or
tie
lla
 et
a
l. 
Ti
ss
ue
En
g 
Pa
rt
 A
20
10
 (3
4)
m
ES
C
R
at
 (S
pra
gu
e
D
aw
le
y)
ac
el
lu
la
r l
un
g
Tr
ac
he
a
21 da
ys
Pr
ox
im
al
-d
ist
al
re
gi
os
pe
ci
fic
CC
10
, p
ro
SP
-C
ex
pr
es
sio
n)
tr
ac
he
ob
ro
nc
hi
al
:
CC
10
, C
K
18
; d
ist
al
lu
ng
: p
ro
SP
-C
,
CD
31
, P
D
G
FR
α
O
tt 
et
 a
l.
N
at
ur
e M
ed
20
10
 (3
3)
H
U
V
EC
(D
sR
ed
)
R
at
 a
ce
llu
la
r
lu
ng
Pu
lm
on
ar
y
ar
te
ry
9 
da
ys
A
ll 
ve
ss
el
s
en
do
th
el
ia
l c
el
ls
A
54
9
R
at
 a
ce
llu
la
r
lu
ng
Tr
ac
he
a
9 
da
ys
A
irw
ay
s/a
lv
eo
li
ai
rw
ay
 / 
al
ve
ol
ar
ep
ith
el
iu
m
H
U
V
EC
(D
sR
ed
)
R
at
 a
ce
llu
la
r
lu
ng
Pu
lm
on
ar
y
ar
te
ry
9 
da
ys
En
tir
e
v
as
cu
la
tu
re
en
do
th
el
ia
l c
el
ls
R
at
 fe
ta
l
lu
ng
 c
el
ls
(G
D1
9–
20
)
R
at
 a
ce
llu
la
r
lu
ng
Tr
ac
he
a
9 
da
ys
A
irw
ay
s/a
lv
eo
li
pr
oS
P-
A
, p
ro
SP
-C
,
Tt
f-1
/N
kx
2.
1 
(A
EC
II)
;
T1
α (
AE
CI
);
V
im
en
tin
(fi
bro
bla
st)
Pe
te
rs
en
 e
t
a
l. 
Sc
ie
nc
e
20
10
 (3
2)
N
eo
na
ta
l
(7d
) l
un
g
ep
ith
el
ia
l
ce
lls
 (r
at)
R
at
 a
ce
llu
la
r
lu
ng
s (
Fis
ch
er
34
4)
Tr
ac
he
a
8 
da
ys
A
lv
eo
la
r, 
sm
al
l
ai
rw
ay
s
CC
SP
 (C
lar
a c
ell
),
pr
oS
P-
C 
(A
EC
II)
,
A
qp
5 
(A
EC
I),
CK
14
(ba
sal
 ce
ll)
Lu
ng
v
as
cu
la
r
en
do
th
el
iu
m
 (r
at)
R
at
 a
ce
llu
la
r
lu
ng
s (
Fis
ch
er
34
4)
Pu
lm
on
ar
y
ar
te
ry
7 
da
ys
M
ic
ro
va
sc
ul
ar
CD
31
Pr
ic
e 
et
 a
l.
Ti
ss
ue
En
gi
ne
er
in
g
Pa
rt
 A
 2
01
0
(31
)
Fe
ta
l l
un
g
(E
17
)
M
s a
cc
el
lu
la
r
lu
ng
s
Tr
ac
he
al
7 
da
ys
A
lv
eo
la
r
CK
18
+/
pr
oS
P-
C+
(A
EC
II)
; n
o C
D1
1b
,
aq
ua
po
rin
-5
,
CC
SP
, C
D
31
, o
r
v
im
en
tin
D
al
y 
et
 a
l.
Ti
ss
ue
 E
ng
Pa
rt
 A
 2
01
1
(39
)
m
B
M
-M
SC
s
M
s a
ce
llu
la
r
lu
ng
Tr
ac
he
a
28 da
ys
Pa
re
nc
hy
m
al
>a
i
rw
ay
(sq
ua
mo
us
)
M
SC
s: 
N
o 
ev
id
en
ce
fo
r
tr
an
sd
iff
er
en
tia
tio
n
Respirology. Author manuscript; available in PMC 2013 August 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Wagner et al. Page 28
R
ef
er
en
ce
C
el
ls 
us
ed
fo
r 
se
ed
in
g
Sc
af
fo
ld
R
ou
te
D
ur
at
i
o
n
D
ist
ri
bu
tio
n
Fi
na
l p
he
no
ty
pe
C1
0 
-h
A
EC
II
(no
n-
tu
m
or
ig
en
ic
)
M
s a
ce
llu
la
r
lu
ng
Tr
ac
he
a
28 da
ys
Pa
re
nc
hy
m
al
N
/A
O
tt 
et
 a
l
A
nn
 T
ho
ra
c
Su
rg
 2
01
1
(37
)
R
at
 fe
ta
l
(G
D1
7–
20
)
pn
eu
m
oc
yt
e
s
R
at
 a
ce
llu
la
r
lu
ng
Tr
ac
he
a
14 da
ys
A
lv
eo
la
r/d
ist
al
br
on
ch
io
le
s>
tr
ac
he
a/
br
on
ch
i
CC
SP
 (a
irw
ay
s);
 T
TF
-
1,
 p
ro
SP
-C
 (a
lve
ola
r)
H
U
V
EC
A
th
ym
ic
 n
ud
e
ra
t
Pu
lm
on
ar
y
ar
te
ry
14 da
ys
Pr
ox
im
al
 to
di
sta
l
v
as
cu
la
tu
re
CD
31
po
s
Sh
am
is 
et
 a
l
Ti
ss
 E
ng
 P
ar
t
C
 2
01
1
(36
)
M
s A
EC
II
(pr
im
ary
 or
P2
)
A
ce
llu
la
r l
un
g
m
ic
ro
sc
af
fo
ld
D
ire
ct
se
ed
in
g
22 da
ys
A
lv
eo
la
r
pr
oS
P-
C/
SP
-C
 (A
EC
II-
lik
e,
 fr
om
 p
rim
ar
y
o
r 
cu
ltu
re
d 
A
EC
II)
;
A
qp
5,
 P
dp
n 
(A
EC
I);
CC
SP
 (p
rim
ary
)
W
al
lis
 e
t a
l
Ti
ss
ue
En
gi
ne
er
in
g
Pa
rt
 C
 2
01
1
(41
)
m
B
M
-M
SC
s
M
s a
ce
llu
la
r
lu
ng
Tr
ac
he
a
14 da
ys
A
lv
eo
la
r
M
SC
s
C1
0 
- h
A
EC
II
(no
n-
tu
m
or
ig
en
ic
)
M
s a
ce
llu
la
r
lu
ng
Tr
ac
he
a
14 da
ys
La
rg
e 
an
d 
Sm
al
l
A
irw
ay
s
sq
ua
m
ou
s
m
o
rp
ho
lo
gy
Bo
nv
ill
ai
n 
et
a
l, 
Ti
ss
ue
 E
ng
Pa
rt
 A
 2
01
2
(38
)
R
he
su
s B
M
-
M
SC
s
R
he
su
s
m
ac
aq
ue
Se
co
nd
ar
y
br
on
ch
us
7 
da
ys
A
lv
eo
la
r s
ep
ta
e,
te
rm
in
al
br
on
ch
io
le
s,
re
sp
ira
to
ry
br
on
ch
io
le
s
M
SC
s p
he
no
ty
pe
R
he
su
s A
D
-
M
SC
s
R
he
su
s
m
ac
aq
ue
Se
co
nd
ar
y
br
on
ch
us
7 
da
ys
A
lv
eo
la
r s
ep
ta
e,
te
rm
in
al
br
on
ch
io
le
s,
re
sp
ira
to
ry
br
on
ch
io
le
s
M
SC
s p
he
no
ty
pe
Je
ns
en
 et
 al
Ti
ss
ue
 E
ng
Pa
rt
 C
 2
01
2
(40
)
m
ES
Cs
 d
iff
. t
o
Tt
f1
po
s /p
ro
SP
-C
po
s
Im
m
er
sio
n
14
 d
ay
A
lv
eo
la
r
Tt
f1
/N
kx
2.
1,
 p
ro
SP
-
C 
(al
ve
ola
r);
PD
G
FR
α
(m
ese
nc
hy
ma
l)
Lo
ng
m
ir
e 
et
a
l. 
C
el
l S
te
m
C
el
l 2
01
2
(61
)
m
ES
Cs
M
s a
ce
llu
la
r l
un
g
Tr
ac
he
a
10 da
ys
H
yp
er
ce
llu
la
r
sh
ee
ts 
(al
ve
ola
r)
ci
lia
te
d 
ce
lls
(ai
rw
ay
s);
 T
1α
n
eg
(al
ve
oli
)
N
kx
2.
1G
FP
M
s a
ce
llu
la
r l
un
g
Tr
ac
he
a
10 da
ys
A
lv
eo
la
r
N
kx
2.
1/
T1
α (
alv
eo
li)
Respirology. Author manuscript; available in PMC 2013 August 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Wagner et al. Page 29
R
ef
er
en
ce
C
el
ls 
us
ed
fo
r 
se
ed
in
g
Sc
af
fo
ld
R
ou
te
D
ur
at
i
o
n
D
ist
ri
bu
tio
n
Fi
na
l p
he
no
ty
pe
Bo
ne
nf
an
t e
t
a
l Bi
om
at
er
ia
ls
20
13
 (4
2)
M
ou
se
B
M
-M
SC
s
M
s a
ce
llu
la
r l
un
g
Tr
ac
he
a
28 da
ys
A
lv
eo
la
r
N
/A
C1
0 
-A
EC
II
(no
n-
tu
m
or
ig
en
ic
)
M
s a
ce
llu
la
r l
un
g
Tr
ac
he
a
28 da
ys
A
lv
eo
la
r
N
/A
So
ko
ce
 v
ic
 et
a
l Bi
om
at
er
ia
ls
20
13
 (4
3)
m
B
M
-
M
SC
s
M
s a
ce
llu
la
r l
un
g
Tr
ac
he
a
28 da
ys
A
lv
eo
la
r
N
/A
C1
0 
-
hA
EC
II
(no
n-
tu
m
or
ig
en
ic
)
M
s a
ce
llu
la
r l
un
g
Tr
ac
he
a
28 da
ys
A
lv
eo
la
r
N
/A
Respirology. Author manuscript; available in PMC 2013 August 01.
